Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05159895 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects
A Phase 1 study, sponsored by Dizal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05159895 is a Phase 1 study that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT05159895, a Phase 1 study, has completed, sponsored by Dizal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, ADME study with single oral administration of \[14C\]-DZD9008 in healthy subjects.
Interventions
- DRUG [14C]-DZD9008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05159895
The ClinicalTrials.gov registry entry for NCT05159895 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-DZD9008 is the first listed.
NCT05159895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05159895 about?
NCT05159895 is a clinical study titled "Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects". This is a phase 1, open-label, ADME study with single oral administration of \[14C\]-DZD9008 in healthy subjects.
What is the current status of trial NCT05159895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-09-24. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT05159895?
The interventions under investigation include: [14C]-DZD9008 (DRUG).
Who is sponsoring clinical trial NCT05159895?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.